130 related articles for article (PubMed ID: 8327848)
1. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis.
Daae LN; Kierulf P; Landaas S; Urdal P
Scand J Clin Lab Invest Suppl; 1993; 215():19-27. PubMed ID: 8327848
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
5. Serum triglycerides and blood coagulation factors VII and X, and plasminogen activator inhibitor-1.
Ohni M; Mishima K; Nakajima K; Yamamoto M; Hata Y
J Atheroscler Thromb; 1995; 2 Suppl 1():S41-6. PubMed ID: 9225231
[TBL] [Abstract][Full Text] [Related]
6. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome.
Andersen P
J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S29-31. PubMed ID: 1283767
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
8. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution.
Avellone G; Di Garbo V; Cordova R; Raneli G; De Simone R; Bompiani G
Thromb Res; 1994 Aug; 75(3):223-31. PubMed ID: 7992233
[TBL] [Abstract][Full Text] [Related]
9. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.
Juhan-Vague I; Alessi MC; Vague P
Ann Med; 1996 Aug; 28(4):371-80. PubMed ID: 8862693
[TBL] [Abstract][Full Text] [Related]
10. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
11. Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
Donders SH; Lustermans FA; van Wersch JW
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):249-56. PubMed ID: 1386533
[TBL] [Abstract][Full Text] [Related]
12. Hypertension and the metabolic cardiovascular syndrome: special reference to premenopausal women.
Os I; Nordby G
J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S15-21. PubMed ID: 1283764
[TBL] [Abstract][Full Text] [Related]
13. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Scarabin PY; Aillaud MF; Amouyel P; Evans A; Luc G; Ferrières J; Arveiler D; Juhan-Vague I
Thromb Haemost; 1998 Nov; 80(5):749-56. PubMed ID: 9843166
[TBL] [Abstract][Full Text] [Related]
14. Effects of androgens on haemostasis.
Winkler UH
Maturitas; 1996 Jul; 24(3):147-55. PubMed ID: 8844628
[TBL] [Abstract][Full Text] [Related]
15. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.
Andersen P; Seljeflot I; Abdelnoor M; Arnesen H; Dale PO; Løvik A; Birkeland K
Metabolism; 1995 May; 44(5):611-6. PubMed ID: 7752909
[TBL] [Abstract][Full Text] [Related]
16. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
Meigs JB; Mittleman MA; Nathan DM; Tofler GH; Singer DE; Murphy-Sheehy PM; Lipinska I; D'Agostino RB; Wilson PW
JAMA; 2000 Jan; 283(2):221-8. PubMed ID: 10634338
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
18. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors.
Dent SB; Peterson CT; Brace LD; Swain JH; Reddy MB; Hanson KB; Robinson JG; Alekel DL
J Nutr; 2001 Sep; 131(9):2280-7. PubMed ID: 11533267
[TBL] [Abstract][Full Text] [Related]
19. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia.
Flack JM; Sowers JR
Am J Med; 1991 Jul; 91(1A):11S-21S. PubMed ID: 1867224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
